The use of minimal residual disease (MRD) provided a more objective measure of induction failure in patients
with pediatric acute lymphoblastic leukemia (ALL) than did morphology, according to the results of a study published recently in the Journal of Clinical Oncology.
Researchers studying two generations of a family affected
by pediatric acute lymphoblastic leukemia (ALL) have identified an inherited variation in the ETV6 gene that is associated with an increased risk of developing the disease.
Researchers at SciLifeLab have published a detailed study of the genomes
of pediatric acute lymphoblastic leukemia (ALL) patients, together with pediatric oncologists from the university hospitals in Göteborg, Stockholm, Umeå and Uppsala.
Changes in an epigenetic mechanism that turns expression of genes on and off may be as important as genetic alterations in
causing pediatric acute lymphoblastic leukemia (ALL), according to a study led by scientists at St. Jude Children's Research Hospital and published in the June 10 online edition of the Journal of Clinical Investigation.
August 30, 2017 UChicago Medicine working to offer breakthrough gene therapy approved today by the FDA The University of Chicago Medicine is one of a limited number of U.S. sites working to offer a breakthrough gene therapy
for pediatric acute lymphoblastic leukemia (ALL), which was just approved by the U.S. Food and Drug Administration.